Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.76 -0.07 (-0.47%)

Delayed Quote Updated: 3:41 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial

April 05, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 03, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals's Return On Capital Employed Insights ↗

March 03, 2023

Via Benzinga

Preview: Aurinia Pharmaceuticals's Earnings ↗

February 27, 2023

Via Benzinga

Why Shares of Aurinia Pharmaceuticals Soared This Week ↗

January 06, 2023

A patent settlement and improved financials sent the stock soaring.

Via The Motley Fool

What's Going On With Aurinia Pharmaceuticals Stock Today? ↗

February 28, 2023

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares are trading higher after the company reported better-than-expected fourth-quarter EPS and sales fig

Via Benzinga

Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates

February 28, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference

February 24, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023

February 07, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals ↗

January 04, 2023

Via Benzinga

Why Is Aurinia Pharmaceuticals (AUPH) Stock Down 30%? ↗

November 03, 2022

Despite strong Q3 earnings, shares of AUPH stock are in steep decline today after it lowered its full-year sales guidance.

Via InvestorPlace

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

These 2 Healthcare Stocks Have Doubled in 2023

February 01, 2023

Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks.

Via MarketBeat

Aurinia Announces PTAB Has Terminated Inter Partes Review

January 25, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office

January 24, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results

January 06, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Tesla, Amazon, Apple, Aurinia Pharma, Vera Therapeutics: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

January 03, 2023

Major Wall Street indices closed in the red on Tuesday, the first trading day of 2023, as concerns over rising rates and inflation still seem to drive investor sentiments.

Via Benzinga

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 03, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 03, 2023

Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.

Via Benzinga

Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals

January 03, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

November 30, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals ↗

November 04, 2022

Aurinia Pharmaceuticals (NASDAQ:AUPH) has observed the following analyst ratings within the last quarter:

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

November 03, 2022

We're starting off the day with a look at the latest news behind the biggest pre-market stock movers for Thursday morning!

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022 ↗

November 04, 2022

Upgrades

Via Benzinga

Recap: Aurinia Pharmaceuticals Q3 Earnings ↗

November 03, 2022

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday ↗

November 04, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry.

Via Benzinga

Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session ↗

November 03, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.